

## DOCUMENT TYPE: GUIDELINE

## Site Applicability

Antenatal fetal surveillance occurs in the Antepartum and Maternal Ambulatory Programs.

## Guideline for Minimum Frequency of Antepartum Nonstress Testing and Ultrasound Surveillance

For all Outpatient Bookings, the following is required:

- 1. Greater than or equal to 26 weeks gestation
- 2. Plan to deliver at BC Women's
- 3. Antenatal Records Parts 1 and 2
- 4. Ultrasound report

Indication	Definition/details	Type of Surveillance	Minimum Frequency	When to start
	One or more of the following: • Low PAPP-A (less than 0.15 MoM) • High AFP (greater	Growth ultrasound		Per EMMA guidelines (or equivalent)
Abnormal serum screen	<ul> <li>than 2.50 MoM)</li> <li>High hCG (greater than 4.00 MoM)</li> <li>High Inhibin A (greater than 3.00 MoM)</li> <li>E3 (estriol) (less than 0.4 MoM)</li> </ul>	NST, AFI & UA Doppler <u>only i</u> f IUGR, GHTN or pre-eclampsia		Per IUGR or GHTN/ pre-eclampsia guidelines
Advanced maternal age	40 years age or more at EDD	NST & AFV assessment	2x/ week	38 weeks
Antepartum hemorrhage	Inpatient	NST	As clinically indicated	At diagnosis*
Abruption (Chronic)	Outpatient	NST	Weekly	At diagnosis*
Assisted reproductive technology	As per other indications as they arise			
Cholestasis of pregnancy	Pruritis without rash with or without abnormal liver enzymes	NST	Weekly (or increase as clinically indicated)	At diagnosis (if greater than or equal to 28 weeks)
		Ultrasound	As clinically indicated	
Decreased fetal movement	Less than 6 distinct fetal movements in 2 hours	NST		
		Ultrasound within 24 hours (if high risk factors or suspicion of IUGR or oligo- hydramnios)	Once (or more if indicated by findings)	At diagnosis*



## **DOCUMENT TYPE: GUIDELINE**

Indication	Definition/details	Type of Surveillance	Frequency	When to start
	type 1 or type 2 (HbA1c	Growth ultrasound	Screening	30 - 32 weeks
Diabetes, insulin- requiring	less than 7% and normal fetal growth)	NST	Weekly	36 weeks
	Gestational	Growth ultrasound	Screening	30 - 32 weeks
Well-controlled	Costational	NST	Weekly	36 weeks
	-type 1 and 2: (HbA1c > 7% and asymmetric	Growth ultrasound	Based on clinical findings	28 -32 weeks Repeat PRN
Diabetes, insulin- requiring continued	macrosomia) -gestational: suboptimal glucose control &/or asymmetric macrosomia)	NST	2x/ week	32 weeks
Poorly controlled	Falling insulin	Growth ultrasound		When clinically indicated
	requirements	NST	2x/ week	
Gastroschisis		NST, AFI & UA Doppler	Weekly	34 weeks
Hypertension -gestational and pre-	BP greater than or equal to 140 and/or dBP greater than or equal to 90	NST, AFI & UAD	2x/ week	At diagnosis*
eclampsia	Severity requiring	NST	Daily	
	admission	AFI & UA Doppler	2x/ week	
Hypertension -pre-existing/chronic	BP ≥ 140 and/or dBP ≥ 90 before 20 weeks or anti-hypertensive therapy before 20 weeks	NST, AFI & UAD	once/ week	35 weeks
Isolated severe		NST	2x/ week	At diagnosis*
oligohydramnios (with intact membranes)	DVP less than 2 cm	AFI & UA Doppler	2x/ week	At diagnosis*
SGA fetus ≥32 weeks gestation	UA Doppler PI <95 <sup>th</sup> %ile AND AC and EFW $\geq$ 3 <sup>rd</sup> %ile	NST, AFI & UA Doppler	Weekly	At diagnosis*
-See appended flow chart. -if fetus SGA at	UA Doppler PI <u>&gt;</u> 95 <sup>th</sup> %ile, OR AC or EFW < 3 <sup>rd</sup> %ile		2x/ week	
<32 weeks gestation, refer to MFM.	UA Doppler waveform with any absent (AEDF) or reversed end-diastolic flow (REDF).		Urgent referral to Maternal-fetal medicine.	
Isolated Polyhydramnios	AFI > 250mm	NST and AFI Doppler	Weekly	At diagnosis*
Maternal conditions (SLE, renal disease, APAS, etc.)	As indicated by co-morbid conditions (hypertension, IUGR, etc.)			
Morbid Obesity	Pre-pregnancy BMI greater than or equal to 35 kg/m <sup>2</sup>	NST	Weekly	34 weeks

C-06-07-60013 Page **2** of **6**  Published Date: 20-Dec-2021 Review Date: 20-Dec-2024

This is a controlled document for BCCH& BCW internal use only – see Disclaimer at the end of the document. Refer to online version as the print copy may not be current.



### DOCUMENT TYPE: GUIDELINE

Indication	Definition/details	Type of Surveillance	Frequency	When to start
Motor Vehicle Accident	Contractions less than 1 in 10 min, no vaginal bleeding, no abdominal pain and normal FHR	Continuous EFM x 4 hours from admission		
	Regular contractions, vaginal bleeding, ABN FHR, pain, low platelets or fibrinogen	Continuous EFM x 24 hours from the event		At diagnosis*
		Ultrasound	Every 3-4 weeks	18-20 weeks
	Dichorionic twins and	NST	2x/ week	37 weeks for twins
	trichorionic triplets	1151	ZX/ Week	35 weeks for triplets
		Ultrasound	Every 2 weeks	16 weeks
	Monochorionic diamniotic			36 weeks for twins
	twins	NST	2x/ week	34 weeks for triplets
Multiple gestations		Growth ultrasound	Every 2 weeks	16 weeks
(assuming no other	Monoamniotic twins	AFI & UA Doppler	2x/ week	At admission (based
complications or IUGR)		NST	2x/ day	on GA for intervention)
	TTTS	Ultrasound	At least weekly	At diagnosis
	No laser	NST	At least 2x/ week	At diagnosis*
	Laser or Bipolar or Selective Reduction	Ultrasound	Weekly x 4, then every 2 weeks	From procedure time
		NST	2x/ week	34 wks
Post dates	Maternal age less than 40 years	NST & AFV assessment	2x/ week	41 weeks
PPROM		NST	3x/ week	At diagnosis*
Preterm labour	While on maintenance tocolysis for 48 hours	NST	Daily	At diagnosis*
	Once contractions have stopped completely	NST	Only if preterm labour returns	
Previous stillbirth	Previous IUFD of unknown etiology in second or third trimester	Serum screening for placental evaluation		
		NST, AFI & UA Doppler	Weekly	32 weeks or 1-2 weeks before previous IUFD
		Growth ultrasound	Every 4 weeks	28 weeks
Red blood cell allo- immunization	Kell antibody: at any titre Other significant antibodies: once titre greater than or equal to	Growth ultrasound and MCA Doppler as per Mari chart and trend	As per MCA PSV chart	At significant titre or 20 weeks previous affected pregnancy/ Kell allo- immunization
	1:16	NST	Weekly	32 weeks



#### DOCUMENT TYPE: GUIDELINE

Indication	Definition/details	Type of Surveillance	Frequency	When to start
Substance use	-Perform NST prior to methadone dose	NST	As per obstetrical indication	
	or minimum 8 hours post	NST	Once at readmission	
	methadone dose -Perform on admission or readmission after absence against medical advice or for other obstetrical indication.	Ultrasound within 24 hours (if high risk factors or suspicion of IUGR or oligo- hydramnios)	As per OB indication	After 28 weeks
Trisomy 21	Fetus diagnosed with trisomy 21 this pregnancy	NST	Weekly	34 weeks
Umbilical Vein Varix		NST	Weekly	At diagnosis*

\* Provided fetus(es) at a gestational age and estimated weight compatible with option for intervention.

GHTN = gestational hypertension

**IUFD** = intrauterine fetal demise

hCG = human chorionic gonadotropin

**IUGR** = intrauterine growth restriction

kg/m<sup>2</sup> = kilograms per metre squared

MCA doppler = middle cerebral artery

MoM = multiples of the median

sBP = systolic blood pressure

SLE = systemic lupus erythematosus

TTTS = twin to twin transfusion syndrome

PAPP-A = pregnancy associated plasma protein A

NST = nonstress test

UA = umbilical artery

 $\mathbf{x} = times$ 

PRN = as needed

etc = et cetera

FHR = fetal heart rate

GA = gestational age

Key:

- AC = Abdominal Circumference AFI = amniotic fluid index; AFV = amniotic fluid volume APAS = antiphospholipid antibody syndroome BMI = basal metabolic index
- **dBP** = diastolic blood pressure
- **DVP** = Deepest vertical pocket
- **EDD** = expected date of delivery
- **EFM** = electronic fetal monitoring

EMMA = evaluating maternal markers of acquired risk for pre-eclampsia

References

- 1. Bahtiyar MO, Funai EF, Rosenberg V, Norwitz E, Lipkind H, Buhimschi C, et al. Stillbirth at term in women of advanced maternal age in the United States: when could the antenatal testing be initiated? American journal of perinatology. 2008 May;25(5):301-4.
- Kenyon AP, Piercy CN, Girling J, Williamson C, Tribe RM, Shennan a H. Obstetric cholestasis, outcome with active management: a series of 70 cases. BJOG: an international journal of obstetrics and gynaecology. 2002 Mar;109(3):282-8.
- Rioseco AJ, Ivankovic MB, Manzur A, Hamed F, Kato SR, Parer JT, et al. Intrahepatic cholestasis of pregnancy: a retrospective case-control study of perinatal outcome. American journal of obstetrics and gynecology. 1994 Mar;170(3):890-5.
- 4. Roncaglia N, Arreghini A, Locatelli A, Bellini P, Andreotti C, Ghidini A. Obstetric cholestasis: outcome with active management. European journal of obstetrics, gynecology, and reproductive biology. 2002 Jan;100(2):167-70.
- 5. Glantz A, Marschall H-U, Mattsson L-A. Intrahepatic cholestasis of pregnancy: Relationships between bile acid levels and fetal complication rates. Hepatology (Baltimore, Md.). 2004 Aug;40(2):467-74.
- 6. Canadian Diabetes Association. Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention



#### DOCUMENT TYPE: GUIDELINE

and Management of Diabetes in Canada. Canadian Journal Of Diabetes. 32(Supplement 1):S1-S201.

- 7. Hutcheon J, Lisonkova S, Magee L, Von Dadelszen P, Woo H, Liu S, et al. Optimal timing of delivery in pregnancies with pre-existing hypertension. BJOG: an international journal of obstetrics and gynaecology. 2010 Nov:1-6.
- 8. Menzies J, Magee L a, Li J, MacNab YC, Yin R, Stuart H, et al. Instituting surveillance guidelines and adverse outcomes in preeclampsia. Obstetrics and gynecology. 2007 Jul;110(1):121-7.
- Magee LA, Pels,A. Helewa,M Rey,E., von Dadelszen P.( May 2014) Diagnosis, Evaluation, and Management of the Hypertensive Disorders of Pregnancy: Executive Summary. SOGC Clinical Practice Guideline, No. 307, May 2014. Journal of obstetrics and gynaecology Canada J Obstet Gynaecol Can 2014;36(5):416–438
- 10. NICE. Hypertension in pregnancy: diagnosis and management. Clinical guideline [CG107] Published date: updated: January 2011 National Institute for Health and Clinical Excellence.
- 11. Cedergren MI. Maternal morbid obesity and the risk of adverse pregnancy outcome. Obstetrics and gynecology. 2004 Feb;103(2):219-24.
- 12. Davies GAL, Maxwell C, McLeod L, Gagnon R, Basso M, Bos H, et al. Obesity in pregnancy. Journal of obstetrics and gynaecology Canada: JOGC = Journal d'obstétrique et gynécologie du Canada: JOGC. 2010 Feb;32(2):165-73.
- 13. Kilpatrick SJ. Trauma in pregnancy. UpToDate. Sep 26, 2017. (Version 39).
- 14. Schiff MA, Holt VL. Pregnancy outcomes following hospitalization for motor vehicle crashes in Washington State from 1989 to 2001. American journal of epidemiology. 2005 Mar;161(6):503-10.
- 15. ACOG. ACOG educational bulletin. Obstetric aspects of trauma management. Number 251, September 1998 (replaces Number 151, January 1991, and Number 161, November 1991). American College of Obstetricians and Gynecologists. International journal of gynaecology and obstetrics 1999 Jan;64(1):87-94.
- 16. Liston R, Sawchuck D, Young D. Fetal health surveillance: antepartum and intrapartum consensus guideline. Journal of obstetrics and gynaecology Canada. 2007 Sep;29(9 Suppl 4):S3-56.
- 17. Morin L, Lim K. Ultrasound in twin pregnancies. Journal of obstetrics and gynaecology Canada 2011 Jun;33(6):643-56.
- 18. Heyborne KD, Porreco RP, Garite TJ, Phair K, Abril D. Improved perinatal survival of monoamniotic twins with intensive inpatient monitoring. American journal of obstetrics and gynecology. 2005 Jan;192(1):96-101.
- Signore C, Freeman RK, Spong CY. Antenatal testing-a reevaluation: executive summary of a Eunice Kennedy Shriver National Institute of Child Health and Human Development workshop. Obstetrics and gynecology. 2009 Mar;113(3):687-701.
- Delaney M, Roggensack A, Leduc DC, Ballermann C, Biringer A, Dontigny L, et al. Guidelines for the management of pregnancy at 41+0 to 42+0 weeks. Journal of obstetrics and gynaecology Canada: JOGC = Journal d'obstétrique et gynécologie du Canada : JOGC. 2008 Sep;30(9):800-23.
- 21. ACOG Practice Bulletin Number 146: Management of Late-Term and Postterm Pregnancies, August 2014. Obstet Gynecol. 2014;124:390-396.
- 22. Zimmermann P, Albäck T, Koskinen J, Vaalamo P, Tuimala R, Ranta T. Doppler flow velocimetry of the umbilical artery, uteroplacental arteries and fetal middle cerebral artery in prolonged pregnancy. Ultrasound in Obstetrics and Gynecology. 1995;5(3):189–197.
- 23. Anteby EY, Tadmor O, Revel A, Yagel S. Post-term pregnancies with normal cardiotocographs and amniotic fluid columns: the role of Doppler evaluation in predicting perinatal outcome. European journal of obstetrics, gynecology, and reproductive biology. 1994 Apr;54(2):93-8.
- 24. Moberg LJ, Garite TJ, Freeman RK. Fetal heart rate patterns and fetal distress in patients with preterm premature rupture of membranes. Obstetrics and gynecology. 1984 Jul;64(1):60-4.
- 25. Nelson KB, Ellenberg JH. Antecedents of cerebral palsy. Multivariate analysis of risk. The New England journal of medicine. 1986 Jul;315(2):81-6.
- 26. Weeks JW. Antepartum testing for women with previous stillbirth. Seminars in perinatology. 2008 Aug;32(4):301- 6.
- 27. Monari F, Facchinetti F. Management of subsequent pregnancy after antepartum stillbirth. A review. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the



#### DOCUMENT TYPE: GUIDELINE

Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians. 2010 Oct;23(10):1073-84.

- 28. Reddy UM. Management of pregnancy after stillbirth. Clinical obstetrics and gynecology. 2010 Sep;53(3):700-9.
- 29. Robson SJ, Leader LR. Management of subsequent pregnancy after an unexplained stillbirth. Journal of perinatology: official journal of the California Perinatal Association. 2010 May;30(5):305-10.
- 30. Berger, H. Gagnon, R. Sermer, M. (July 2016) Diabetes in Pregnancy Journal of obstetrics and gynaecology Canada: 2016; 38(7):667-679 No. 334 (Replaces No. #121, November 2002).

## **Developed By**

BCW Maternal Newborn Program – Maternal Fetal Medicine Specialists

#### **Version History**

DATE	DOCUMENT NUMBER and TITLE	ACTION TAKEN
28-Nov-	C-06-07-60013 Antepartum Nonstress Testing	Approved at: Perinatal Best Practice
2021	Frequency Ultrasound Surveillance	Committee

## Disclaimer

This document is intended for use within BC Children's and BC Women's Hospitals only. Any other use or reliance is at your sole risk. The content does not constitute and is not in substitution of professional medical advice. Provincial Health Services Authority (PHSA) assumes no liability arising from use or reliance on this document. This document is protected by copyright and may only be reprinted in whole or in part with the prior written approval of PHSA.